↓ Skip to main content

Dove Medical Press

Article Metrics

Iron deficiency anemia in patients with inflammatory bowel disease

Overview of attention for article published in Clinical and Experimental Gastroenterology, June 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#23 of 306)
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news
2 news outlets
twitter
2 tweeters

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
122 Mendeley
Title
Iron deficiency anemia in patients with inflammatory bowel disease
Published in
Clinical and Experimental Gastroenterology, June 2013
DOI 10.2147/ceg.s43493
Pubmed ID
Authors

Neil Goldberg

Abstract

Iron deficiency anemia is the most common form of anemia worldwide, caused by poor iron intake, chronic blood loss, or impaired absorption. Patients with inflammatory bowel disease (IBD) are increasingly likely to have iron deficiency anemia, with an estimated prevalence of 36%-76%. Detection of iron deficiency is problematic as outward signs and symptoms are not always present. Iron deficiency can have a significant impact on a patient's quality of life, necessitating prompt management and treatment. Effective treatment includes identifying and treating the underlying cause and initiating iron replacement therapy with either oral or intravenous iron. Numerous formulations for oral iron are available, with ferrous fumarate, sulfate, and gluconate being the most commonly prescribed. Available intravenous formulations include iron dextran, iron sucrose, ferric gluconate, and ferumoxytol. Low-molecular weight iron dextran and iron sucrose have been shown to be safe, efficacious, and effective in a host of gastrointestinal disorders. Ferumoxytol is the newest US Food and Drug Administration-approved intravenous iron therapy, indicated for iron deficiency anemia in adults with chronic kidney disease. Ferumoxytol is also being investigated in Phase 3 studies for the treatment of iron deficiency anemia in patients without chronic kidney disease, including subgroups with IBD. A review of the efficacy and safety of iron replacement in IBD, therapeutic considerations, and recommendations for the practicing gastroenterologist are presented.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Spain 1 <1%
Unknown 119 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 18 15%
Student > Master 17 14%
Student > Postgraduate 13 11%
Other 12 10%
Researcher 10 8%
Other 27 22%
Unknown 25 20%
Readers by discipline Count As %
Medicine and Dentistry 49 40%
Agricultural and Biological Sciences 13 11%
Nursing and Health Professions 6 5%
Psychology 4 3%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 16 13%
Unknown 30 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2022.
All research outputs
#1,655,776
of 22,757,090 outputs
Outputs from Clinical and Experimental Gastroenterology
#23
of 306 outputs
Outputs of similar age
#14,751
of 194,250 outputs
Outputs of similar age from Clinical and Experimental Gastroenterology
#2
of 11 outputs
Altmetric has tracked 22,757,090 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 306 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,250 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.